In this study, we investigated the preclinical activity of patient-derived CSPG4-CAR.CIK against patient-derived melanoma cells, focusing on models with defective expression of HLA-I molecules, as this setting might provide a representative perspective of the challenging clinical scenario. The gene discussed is CSPG4; the disease is melanoma.